Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.
Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for...
Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based th...
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.26) per share.
HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.
HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.
